1 / 8

Misoprostol for the Prevention of Postpartum Hemorrhage

Misoprostol for the Prevention of Postpartum Hemorrhage. Lisa J. Thomas, MD, FACOG Women’s Commission for Refugee Women and Children. Misoprostol . Background PGE1, heat stable, inexpensive Indications, Dosage, and Routes Abortion, Incomplete Abortion, Induction of Labor

lan
Download Presentation

Misoprostol for the Prevention of Postpartum Hemorrhage

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Misoprostol for the Prevention of Postpartum Hemorrhage Lisa J. Thomas, MD, FACOG Women’s Commission for Refugee Women and Children

  2. Misoprostol • Background • PGE1, heat stable, inexpensive • Indications, Dosage, and Routes • Abortion, Incomplete Abortion, Induction of Labor • Prevention and Treatment of PPH • Global Burden of PPH • 25% of Maternal Deaths Worldwide • 34% of Maternal Deaths in Africa (hemorrhage) • Impossible to predict based on risk factors • Urgent BEMOC/CEmOC • Prevention is critical • AMTSL • Oxytocin is drug of choice in hospital settings • Skilled care required

  3. Growing Evidence for Effectiveness • Oral Misoprostol in preventing postpartum haemorrhage in resource-poor communities: A Randomized Controlled Trial. Derman et al, The Lancet 2006… • DB, placebo-controlled* (1620 randomized) • Miso 600 mcg po within 5 mins cord clamp/cut • Expectant management* third stage of labor • Misoprostol • Less blood loss • Less blood transfusion • Increased shivering and fever

  4. WHO Recommendations for the Prevention of PPH • “In the absence of AMTSL, a uterotonic drug (oxytocin or misprostol) should be offered by a health worker trained in its use for prevention of PPH” • Includes auxiliary nurse-midwives, community midwives, village midwives, and health visitors if they have been specially trained

  5. FIGO/ICM Call to Action • National obstetric and midwifery associations to lead efforts to implement miso/PPH • Address legislative, regulatory, and policy barriers • Call upon national regulatory agencies and policy makers to approve miso for PPH prevention and treatment

  6. Misoprostol Registration(for Prevention of PPH) • Registration gives license to market a specific product for a specific indication • Legalizes drug import and sale • Registration dossier prepared/submitted by a manufacturer/distributor pair • Decision made by country’s drug regulatory authority • Currently registered • Nigeria, India, Nepal, Bangladesh • Registration underway* • Indonesia, Egypt, Ethiopia, Tanzania, Zambia *Dossier prepared and submitted or in process

  7. Next Steps • Community Based PPH Prevention • Distribution by CHVs with client education • Invest in training and supervision • SAFE (prevent misuse) • PPH prevention as an indication for use of misoprostol on WHO essential medicines list • More research on optimal dose/route (Lower dose)

  8. Websites • http://whqlibdoc.who.int/hq/2007/WHO_MPS_07.06_eng.pdf • www.accesstohealth.org • www.venturestrategies.org • http://www.pphprevention.org/publications.php#Technical_Briefs

More Related